Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention

The elevated methionine (MET) use by cancer cells is termed MET dependence and may be the only known general metabolic defect in cancer. Targeting MET by recombinant methioninase (rMETase) can arrest the growth of cancer cells in vitro and in vivo. We previously reported that rMETase, administrated...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cell Cycle
Autori principali: Kawaguchi, Kei, Han, Qinghong, Li, Shukuan, Tan, Yuying, Igarashi, Kentaro, Kiyuna, Tasuku, Miyake, Kentaro, Miyake, Masuyo, Chmielowski, Bartosz, Nelson, Scott D., Russell, Tara A., Dry, Sarah M., Li, Yunfeng, Singh, Arun S., Eckardt, Mark A., Unno, Michiaki, Eilber, Fritz C., Hoffman, Robert M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2018
Soggetti:
Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5914727/
https://ncbi.nlm.nih.gov/pubmed/29187018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2017.1405195
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi